Literature review of human papillomavirus vaccine acceptability among women over 26 years

Vaccine. 2009 Mar 10;27(11):1668-73. doi: 10.1016/j.vaccine.2009.01.035. Epub 2009 Feb 3.

Abstract

Vaccines for the human papillomavirus (HPV) are currently licensed for females, ages 9 through 26 years old in the U.S., and for adult women up to 45 years in some countries such as Australia. As licensure for adult women, over 26 years, is sought in other countries, it will be important to determine the acceptability to them. We reviewed the available articles on adult opinions and acceptability of vaccinating women against HPV. Predictors of acceptability included barriers, knowledge, risk, age, and marital status. Overall, acceptability rates were high, if adequate information was given and the cost was affordable.

Publication types

  • Review

MeSH terms

  • Adult
  • Communication
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Papillomavirus Vaccines / adverse effects
  • Papillomavirus Vaccines / economics
  • Papillomavirus Vaccines / therapeutic use*
  • Patient Acceptance of Health Care*
  • Risk
  • Socioeconomic Factors
  • Women*

Substances

  • Papillomavirus Vaccines